09 May 2018 Research

Sharing this exciting news: a treatment advance for childhood leukaemia

A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades.

“We are excited at this breakthrough in the treatment for childhood leukaemia. CAR-T cell therapy gives those children who do not respond to chemotherapy treatment a real chance of a long-term cure. We welcome this significant step forward which will give hope to families whose children are affected by leukaemia.” 

Dr Maria Gilleece, Director, Yorkshire Blood and Marrow Transplant Programme and a member of the Leukaemia UK Medical Panel.

Follow this link to read this BBC news story.

Related posts

“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers

17 April 2024

“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers

New research by Leukaemia UK which could reduce the side-effects of treatment for acute myeloid leukaemia (AML) welcomed by family affected by the disease.   A family who was devastated when…

UK’s top chefs unite at gastronomic spectacular to raise funds for life-saving leukaemia research

5 July 2023

UK’s top chefs unite at gastronomic spectacular to raise funds for life-saving leukaemia research

Twenty of the most accomplished and innovative chefs from the UK food scene will gather at The Dorchester on Monday 18th September 2023 for ‘Who’s Cooking Dinner?’, a one-of-a-kind night…

Cost of Living with Leukaemia Fund launches

16 November 2022

Cost of Living with Leukaemia Fund launches

Leukaemia Care and Leukaemia UK have launched a new financial support service, the Cost of Living with Leukaemia Fund, in response to the cost of living crisis in the UK….

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.